Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
What are the benefits of You First?
You First is a nurse-led service for Cosentyx patients, tailored to meet individual demands and designed to work alongside the expertise of the NHS healthcare team.
Did you know that in a recent survey 100% of Cosentyx patients receiving support from the You First support programme said they would recommend the service to friends and family?*1 It’s hardly surprising with a patient satisfaction rating of 99.84%.*1
How many Cosentyx patients has You First supported?
- You First is for NHS patients who are receiving Cosentyx or for whom the prescribing decision has been made
- A service level agreement is required for each NHS organisation participating
- You First is a patient support programme developed and funded by Novartis Pharmaceuticals UK Limited
What does the You First programme offer?
The You First programme is offered for up to 3 years
The programme is a service tailored to the needs of both the trust and the patient
100% of You First patients would recommend the service to friends and family (n=465).*
99.5% mean score for the politeness and professionalism of nurses (n=465).*
Watch now: Hear first-hand experiences from a You First patient
Ready to sign up?
To express your interest in signing up to the You First programme, please get in touch by clicking here.
The You First team will respond to all enquiries within 48 hours.
*Patients rated the care they received from their You First nurse, provided by Bionical, on a scale of 0–4 (0 = very dissatisfied, 4 = very satisfied); the mean score was converted into a percentage (n=465).
DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate.
- Novartis Data on File Secukinumab You First DoF UK 1 – March 2021.
- Novartis Data on file. You First Account Data – June 2021.